In January, Germany's cost watchdog decided that Dendreon's--now Valeant's--Provenge had no added benefit for men with metastatic prostate cancer. But now, it's changing its tune.
Aduro Biotech is the latest to try its hand at an IPO, and it laid out its case for an $86 million IPO last week.
The Bill & Melinda Gates Foundation announced this week it's betting on CureVac, a move both Sanofi and Boehringer Ingelheim made last year, committing to an mRNA technology designed to make vaccines less expensive and easier to make.
After a handful of large-scale monotherapy flops for cancer vaccines, many companies now think pairing them up as part of immunotherapy combos might be the way to go. And immuno-oncology pioneer Bristol-Myers Squibb just made a big bet that that's the case.
In another step forward for cancer vaccine combos, Aduro Biotech announced Thursday that an investigator-led Phase II trial of its GVAX and CRS-207 for pancreatic cancer with Opdivo, Bristol-Myers Squibb's PD-1 drug, would begin.
Valeant only just picked up Provenge and other assets from bankrupt Dendreon, but it's already trumpeting positive preliminary data for the flailing cancer vaccine. On Wednesday, it announced Phase II results showing that the immune response from Provenge continues two years after biochemically recurrent prostate cancer patients complete treatment.
On Tuesday, Bavarian Nordic announced positive survival data from a Phase I combination study of its active prostate cancer immunotherapy candidate Prostvac and Bristol-Myers Squibb's Yervoy (ipilimumab), an immune checkpoint inhibitor.
Advaxis is pushing full steam ahead to test its cancer vaccine candidates in immunotherapy combos, and it just scored another $23 million to help its hopefuls through the clinic.
Advaxis, on a partnering spree after joining with Merck and AstraZeneca to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte to trial one of its prospects in cervical cancer.
It's official: Valeant will be the new owner of Dendreon's Provenge.